Antibody-Drug Conjugates

ADC Bio secures funding to further manufacturing plans

16-Nov-2018 By Ben Hargreaves

The company announced an investment of £2.5m to design its downstream formulation and filling operations.

AstraZeneca sells US rights to RSV drug for $1.5bn

14-Nov-2018 By Maggie Lynch

AstraZeneca announced it will sell US rights to Synagis to Sobi, to focus on its collaborative RSV therapy.

Takeda proposes sale of IBD pipeline to close Shire deal

31-Oct-2018 By Maggie Lynch

Takeda is in talks to sell Shire’s experimental inflammatory bowel disease pipeline in an effort to meet European regulators approval for the acquisition.

Lonza expands manufacturing sites for larger ADC payloads

16-Oct-2018 By Maggie Lynch

Lonza Pharma & Biotech will expand two of its manufacturing sites to reach the capabilities necessary to produce compounds bio-conjugates through to commercialization.

Merck biosimilar made available on the US VA National Formulary

12-Oct-2018 By Maggie Lynch

The US Department of Veteran Affairs awarded a national contract for Merck’s biosimilar to be available on its National Formulary.

Daiichi-Merck partnership lines up Keytruda combo therapy

09-Oct-2018 By Maggie Lynch

Daiichi Sankyo announced it has entered into a clinical trial collaboration agreement with Merck & Co. to evaluate an investigational lung cancer treatment.

Regeneron and Sanofi receives first US FDA approval for PD-1 treatment

03-Oct-2018 By Maggie Lynch

The US FDA approved the first drug created by the 2015 partnership between Regeneron and Sanofi to research and develop immuno-oncology therapies.

Partnership to provide oncology portfolio with a translational platform

19-Sep-2018 By Maggie Lynch

Mitra Biotech and Glenmark Pharmaceuticals have partnered to advance research on Glenmark’s immuno-oncology treatments using Mitra’s platform.

US FDA approves expanded label for Merck’s Keytruda as first-line treatment for NSCLC

22-Aug-2018 By Maggie Lynch

The US FDA has approved an expanded label for Merck’s Keytruda in combination with pemetrexed and platinum chemotherapy.

Daiichi Sankyo and Glycotope reach agreement for “first-in-class” ADC

03-Aug-2018 By Maggie Lynch

Daiichi Sankyo and Glycotope have signed a licensing agreement to develop an antibody-drug conjugate that enables tumor-specific binding to TA-MUC1.

ADC Bio: Biotech may 'hold the key' to innovation adoption

08-Jun-2018 By Flora Southey

CDMOs need to respond to biotech innovation at an R&D level to improve efficiency in antibody-drug conjugate manufacturing, says ADC Bio.

The Golden Ticket: Sanofi, Meditope initiate research collaboration to explore bioconjugation tech

09-May-2018 By Melissa Fassbender

Sanofi has awarded Meditope Biosciences a BioLabs’ “Golden Ticket” to support the development of its bioconjugation platform and create new antibody-based therapeutic constructs.